Change of Adviser

RNS Number : 3201R

Redx Pharma plc

08 March 2016

 

                                                                                                              8 March 2016

REDX PHARMA PLC

("Redx" or "the Company")

Appointment of Cantor Fitzgerald Europe as

Nominated Adviser & Broker

The Board of Redx Pharma Plc is pleased to announce the appointment of Cantor Fitzgerald Europe as its Nominated Adviser and Broker with immediate effect.

For more information please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Cantor Fitzgerald Europe (Nomad & Broker)	T: 020 7894 7000
Phil Davies / Michael Reynolds
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

APPAKODDFBKDONK